Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. - Wikidata - awgldk - TriplyDB

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

http://www.wikidata.org/entity/Q35080053

about

Identifying Recent HIV Infections: From Serological Assays to Genomics A Comparison of South African National HIV Incidence Estimates: A Critical Appraisal of Different Methods Viral and Host Characteristics of Recent and Established HIV-1 Infections in Kisumu based on a Multiassay Approach.Performance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection.A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay Evaluation of dried blood spots with a multiplex assay for measuring recent HIV-1 infection Sample size methods for estimating HIV incidence from cross-sectional surveys.How can we better identify early HIV infections?Performance of Bio-Rad and Limiting Antigen Avidity Assays in Detecting Recent HIV Infections Using the Quebec Primary HIV-1 Infection Cohort.Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana Early HIV Infections Among Men Who Have Sex with Men in Five Cities in the United States.Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study.Pairwise diversity and tMRCA as potential markers for HIV infection recency Longitudinal trends of recent HIV-1 infections in Slovenia (1986-2012) determined using an incidence algorithm.Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays.Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence.Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection.Assays for estimating HIV incidence: updated global market assessment and estimated economic value.Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial.Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection.

P2860

Q26778001-BD537650-2809-44BE-AA6D-2A6C2E2C298A Q28546966-3F5BFEED-1D68-43C3-AAF1-13EFE32A8232 Q30830042-377CBC13-AA5B-4510-A84B-5ADCA95A4639 Q33637675-6B0E3223-9FCC-499D-841C-A7A7F95EBE3B Q33812743-6013F83B-68E0-4F4E-A029-6DB0F9936F82 Q33916829-F626E338-8F4A-474D-ABA2-107CE45F2F6B Q34214893-411403D0-83E2-46AA-8E36-03F45A9B4487 Q35753750-D2E2D0F8-C039-4D43-BCB3-1BDA5888C372 Q35814304-1E60B925-D7E0-4963-8723-26664A8A1708 Q36029177-464AD4B1-53F4-47FA-A9C6-A3BA9AA5100D Q36110367-ABDED438-AAE7-426A-9D1B-9F9EA3BBFB52 Q37422022-649342F3-333F-4E7D-A81B-5463A88EBEEB Q37624455-8BD1F93D-3F39-4959-B64D-962D020C1004 Q37646636-DA443FC3-5777-4753-9F4E-1E763728BFF6 Q38426046-0B2F997E-A074-4C04-8977-F251CC59B4BF Q40226580-C0583E03-67C9-4FF2-ACA8-2BDDBB6E35F2 Q40285384-AA07EA0B-5739-49B0-B1C3-A0EEF5B8C4DC Q47151503-9CD80A06-7D39-4101-88D7-9A1BD1F79FB1 Q48253997-26FBCCC9-2255-4F79-94CD-F9256AEA2B28 Q50089242-ADBDB8D9-8556-40CA-91FA-F4CEA0114893 Q52681670-C57B8E3C-DA5C-4C7A-884D-DB9B116F5CD5

P2860

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

http://www.wikidata.org/entity/Q35080053

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Performance of a limiting-anti ...... ncidence in the United States.

@ast

Performance of a limiting-anti ...... ncidence in the United States.

@en

type

label

Performance of a limiting-anti ...... ncidence in the United States.

@ast

Performance of a limiting-anti ...... ncidence in the United States.

@en

prefLabel

Performance of a limiting-anti ...... ncidence in the United States.

@ast

Performance of a limiting-anti ...... ncidence in the United States.

@en

P1433

Q35080053-9D6AA91C-1E65-4777-A182-CD3C4345C077

P1476

Q35080053-CE6D5DF8-EA1C-4410-B800-66AB468BFDE7

P2093

Q35080053-0445514C-D7FF-437C-BE8E-5606365A3C97

Q35080053-3BCE7E3A-E34A-42B1-8020-72DCEB4EC36C

Q35080053-791F4050-9613-4533-8D39-93C5EBA03A16

Q35080053-7B160577-FBAB-4F2F-8297-299DD73F1793

Q35080053-89CB41AF-C8C0-4090-8736-7DFBDF3C9350

Q35080053-95773E4B-7CAE-4A1E-9E6D-C179B4B68195

Q35080053-9ABA22DE-8F8A-464B-B6F9-AB3F84870801

Q35080053-B2854528-978E-441E-BCC1-31282045EE6F

Q35080053-B31EB203-E4FB-4049-8405-F6352C9384FD

Q35080053-CBB5A125-D7A4-438E-929C-D1D929328A16

P2860

Q35080053-00AC8E7D-BADE-45CE-A302-4BC6FFF67447

Q35080053-0408D9D2-CB62-48FE-BDC1-8465E2261CB8

Q35080053-1181ED2A-4A02-4F74-A39F-F52020068B2D

Q35080053-13E5694A-B85F-47EB-AECB-8E4944CFE645

Q35080053-1BF34B7E-3A62-4311-B4DB-F6F1357FFC9C

Q35080053-1CA24B65-EC86-440C-AE28-943BBE49714B

Q35080053-1F79633C-593E-4203-A4B9-ECD3D10DDA1F

Q35080053-201E0DCA-90EE-47E5-A753-3AE4DB496B07

Q35080053-2A105A86-8552-4855-8C08-E54E94048BCD

Q35080053-2E8E99FD-75A0-474B-A2C7-AFB4421840C7

P304

Q35080053-7D0D7D73-32AF-45EC-804E-7BEBA769C4CA

P31

Q35080053-D725CB5C-1EFB-41B9-BA98-2BFD0D358F30

P356

Q35080053-074BAF67-B0F6-4F3B-B6C8-8D22A3CEA39E

P407

Q35080053-4F6E33CD-F5A8-4F93-BDDA-3633AAF47404

P433

Q35080053-B3568E5A-DE36-4E15-A6F3-1DA07F4AD8AF

P478

Q35080053-F8BFBAF4-333A-4603-83A0-043DD56D0EA5

P50

Q35080053-2BDF0C03-C777-4DC7-93C0-340D917C4F11

Q35080053-6F660D15-2946-46E6-9383-62D197F60F47

Q35080053-7E6470DD-B25C-4FDA-9B74-7879C5886401

Q35080053-99C74C44-0118-4FA4-8B1A-51F660DBAA8E

Q35080053-9EFE7AB7-2B66-4714-9F6E-272A9649303F

Q35080053-A5E730A1-B9B5-48F6-ADD2-6AC93EF0CE90

Q35080053-A844EA02-3BB5-4AD7-AF94-2D1AAAE34089

Q35080053-EFB7960C-D549-4DAB-A9FE-8B8282326DAF

P577

Q35080053-EA471AB0-04A2-45F1-83AB-D6E0CF0CAAA2

P5875

Q35080053-91EA9CE8-E840-44DE-91C6-D9B3AB3C3737

P698

Q35080053-18D06AE8-DC6A-4C62-BEB6-E0FCB84FEF66

P932

Q35080053-428F6D6A-567E-4DB7-9E7B-FD119345AFC9

P356

JOURNAL.PONE.0082772

P1433

P1476

Performance of a limiting-anti ...... ncidence in the United States.

@en

P2093

Andrew F Longosz

http://www.w3.org/2001/XMLSchema#string

George R Seage

http://www.w3.org/2001/XMLSchema#string

Gregory D Kirk

http://www.w3.org/2001/XMLSchema#string

Jacob Konikoff

http://www.w3.org/2001/XMLSchema#string

Jessica E Justman

http://www.w3.org/2001/XMLSchema#string

Joelle Brown

http://www.w3.org/2001/XMLSchema#string

Matthew M Cousins

http://www.w3.org/2001/XMLSchema#string

Richard D Moore

http://www.w3.org/2001/XMLSchema#string

Sally L Hodder

http://www.w3.org/2001/XMLSchema#string

Shruti H Mehta

http://www.w3.org/2001/XMLSchema#string

P2860

Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061

Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies

Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.

Measuring the HIV/AIDS epidemic: approaches and challenges.

HIV acquisition among women from selected areas of the United States: a cohort study

The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants.

Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion.

Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward.

P304

e82772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0082772

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Oliver Laeyendecker

Joseph B Margolick

P577

2013-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259567574

http://www.w3.org/2001/XMLSchema#string

P698

24386116

http://www.w3.org/2001/XMLSchema#string

P932

3873916

http://www.w3.org/2001/XMLSchema#string